injuries; other neurological symptoms; autoimmune disorder; numbness around her mouth and arm; severe headache; dizziness; numbness around her mouth and arm; blurred vision; alopecia; telogen effluvium; Information has been received from a lawyer regarding a case in litigation referring to a 38 years old female patient(pt). Information about concurrent condition, medical history and concomitant medication was not reported. Prior to receiving her quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL) injections, pt had no autoimmune diseases, and she was in her usual state of health. Pt routinely received Pap smears, as recommended by her doctors, on 24-OCT-2019, the patient was vaccinated with the first dose of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL) (strength, dose, route, lot # and expiration date were not reported) for prophylaxis. By December 2019, pt started to notice that her hair was falling out in larger amounts than usual, far more than regular daily shedding, but  pt did not think much of it at the time. On 15-JAN-2020,  pt visited her regular doctor, where she received her second dosage of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL). Unfortunately,  pt's hair continued to fall out in large amounts and pt was ultimately diagnosed with alopecia and telogen effluvium in April 2020. Further, in September 2020, pt had a sudden onset of severe headache for approximately three weeks. She also experienced dizziness, numbness around her mouth and arm, and blurred vision. Since receiving her quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL) injections, pt had continued to experience hair loss and other neurological symptoms, injuries she believes were triggered by quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL). These conditions affect her daily life, causing her extreme discomfort and embarrassment. Pt contended that her quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL) injections caused her to develop serious and debilitating injuries, including but not limited to autoimmune disease, including alopecia and telogen effluvium, as well as a constellation of adverse symptoms, complications, injuries, and other adverse events, many of which are alleged herein and all of which were caused by quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL) or otherwise linked to her quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL) induced autoimmune disorder. As a proximate result of Merck's wrongful acts and omissions and its negligent and fraudulent testing, labeling, manufacturing, marketing and promotion of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL), pt had suffered and continued to suffer severe and permanent physical injuries and disfigurement, and associated symptomology and had suffered severe and permanent emotional injuries, including pain and suffering. Pt also had a substantial fear of suffering additional and ongoing harms, including but not limited to now being at an increased risk of cancer, and future symptoms and harms associated with her autoimmune disease and other injuries caused by quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL). As a direct and proximate result of her quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL)-induced injuries, pt had suffered and continues to suffer economic losses, including considerable financial expenses for medical care and treatment, and diminished income capacity, and she will continue to incur these losses and expenses in the future. The outcome of the events was not recovered. The causality assessment was considered as related by the lawyer.  The lawyer considered all the events to be disability. Upon internal review, autoimmune disorder was determined to be medically significant.